- Home
- DAWN vs ANIP Comparison
DAWN vs ANIP Comparison
Compare DAWN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- ANIP
- Stock Information
- Founded
- DAWN 2018
- ANIP 2001
- Country
- DAWN United States
- ANIP United States
- Employees
- DAWN N/A
- ANIP N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- ANIP Health Care
- Exchange
- DAWN Nasdaq
- ANIP Nasdaq
- Market Cap
- DAWN 1.3B
- ANIP 1.2B
- IPO Year
- DAWN 2021
- ANIP N/A
- Fundamental
- Price
- DAWN $12.24
- ANIP $58.35
- Analyst Decision
- DAWN Strong Buy
- ANIP Buy
- Analyst Count
- DAWN 7
- ANIP 7
- Target Price
- DAWN $36.33
- ANIP $77.33
- AVG Volume (30 Days)
- DAWN 1.1M
- ANIP 249.7K
- Earning Date
- DAWN 02-24-2025
- ANIP 02-27-2025
- Dividend Yield
- DAWN N/A
- ANIP N/A
- EPS Growth
- DAWN N/A
- ANIP N/A
- EPS
- DAWN N/A
- ANIP N/A
- Revenue
- DAWN $101,953,000.00
- ANIP $555,456,000.00
- Revenue This Year
- DAWN N/A
- ANIP $25.48
- Revenue Next Year
- DAWN $35.22
- ANIP $20.24
- P/E Ratio
- DAWN N/A
- ANIP N/A
- Revenue Growth
- DAWN N/A
- ANIP 23.60
- 52 Week Low
- DAWN $11.13
- ANIP $52.50
- 52 Week High
- DAWN $18.07
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- DAWN 45.74
- ANIP 61.44
- Support Level
- DAWN $11.13
- ANIP $52.74
- Resistance Level
- DAWN $12.74
- ANIP $55.21
- Average True Range (ATR)
- DAWN 0.51
- ANIP 1.52
- MACD
- DAWN 0.06
- ANIP 0.55
- Stochastic Oscillator
- DAWN 51.15
- ANIP 86.04
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.